ROBERT F GAGEL to Pheochromocytoma
This is a "connection" page, showing publications ROBERT F GAGEL has written about Pheochromocytoma.
Connection Strength
1.059
-
Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004 Aug; 89(8):4142-5.
Score: 0.202
-
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
Score: 0.129
-
Pheochromocytoma, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1994 Apr 14; 330(15):1090-1.
Score: 0.099
-
The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
Score: 0.095
-
The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010 Aug; 31(4):578-99.
Score: 0.076
-
The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med. 1988 Feb 25; 318(8):478-84.
Score: 0.065
-
Impact of prospective screening for multiple endocrine neoplasia type 2. Henry Ford Hosp Med J. 1987; 35(2-3):94-8.
Score: 0.060
-
Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006 Aug; 91(8):2851-8.
Score: 0.057
-
Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr; 198(4):525-34; discussion 534-5.
Score: 0.049
-
Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res. 2000 Nov 15; 60(22):6223-6.
Score: 0.039
-
Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery. 1999 Dec; 126(6):1097-103; discussion 1103-4.
Score: 0.037
-
Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management. Cancer Treat Res. 1997; 89:421-41.
Score: 0.030
-
Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery. 1996 Dec; 120(6):1064-70; discussion 1070-1.
Score: 0.030
-
Natural history of the familial medullary thyroid carcinoma-pheochromocytoma syndrome and the identification of preneoplastic stages by screening studies: a five-year report. Trans Assoc Am Physicians. 1975; 88:177-91.
Score: 0.026
-
Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990 Sep; 19(3):613-35.
Score: 0.019
-
Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989 Nov 15; 111(10):802-6.
Score: 0.018
-
The role of genetics in the surgical management of familial endocrinopathy syndromes. J Am Coll Surg. 2003 Nov; 197(5):818-31.
Score: 0.012
-
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996 Nov 20; 276(19):1575-9.
Score: 0.007
-
The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet. 1989 Feb; 44(2):208-15.
Score: 0.004
-
Natural history of familial medullary thyroid carcinoma: effect of a program for early diagnosis. N Engl J Med. 1978 Nov 02; 299(18):980-5.
Score: 0.002
-
Adrenal medullary hyperplasia. A morphometric analysis in patients with familial medullary thyroid carcinoma. Am J Pathol. 1976 Apr; 83(1):177-96.
Score: 0.002